Clinical Trials Logo

Clinical Trial Summary

Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options. To request access, use Responsible Party contact information provided in this record.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04853602
Study type Expanded Access
Source Morphogenesis, Inc.
Contact Michael JP Lawman, PhD
Phone 813-875-6600
Email [email protected]
Status Available

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT02978625 - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Phase 2
Recruiting NCT04393753 - Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Recruiting NCT04291885 - Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma Phase 2
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Terminated NCT02054884 - F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Phase 2
Completed NCT02514824 - MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03370861 - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Recruiting NCT03210935 - French National Database of Rare Dermatological Cancers
Recruiting NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Phase 1
Not yet recruiting NCT04874831 - Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) Phase 2
Completed NCT00765193 - The Impact of Total Body Skin Examination on Skin Cancer Detection N/A
Not yet recruiting NCT04272034 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04792073 - Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma Phase 2
Not yet recruiting NCT04590781 - Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04160065 - Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC Phase 1
Recruiting NCT03071406 - Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Phase 2
Completed NCT00346385 - BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1